Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
Le Lézard3d
BD Expands Capacity for Advanced Prefillable Syringes and Enhances Injection Experience for the Next Generation of Biologics
BD (Becton, Dickinson and Company) , a leading global medical technology company, announced the commercial release of the BD Neopaktm XtraFlowtm Glass Prefillable Syringe and the latest capacity ...
Business Insider5d
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
We are excited to see efti in combination with KEYTRUDA now driving a 1.9-fold increase in responses ... E+P continues to ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
FierceBiotech7d
ESMO: IO Biotech's vaccine and Keytruda combo hits primary endpoint in phase 2 squamous cell carcinoma trial
Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...
Hosted on MSN8d
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
This week, the FDA approved J&J’s JNJ Tremfya for treating an inflammatory bowel disease condition (“IBD”), ulcerative ...
clinicaltrialsarena8d
ESMO 2024: Moderna’s mRNA solid tumour vaccine shows early promise
Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...
New cancer jab that 'primes body to recognise and fight tumours'
The jab, known as mRNA-4359 and developed by Moderna, is aimed at people with advanced melanoma, lung cancer and other solid ...
Le Lézard11d
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
ChromaDex Corp. , the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to announce the second wave of intravenous (IV) wellness clinics ...
AMBCrypto14d
Why INJ faltered above $17.50 despite Injective’s breakthroughs
Injective Labs, the research and development company behind Injective [INJ], has introduced a groundbreaking tokenized index for the BlackRock USD Institutional Digital Liquidity Fund. The BUIDL Index ...
Nasdaq15d
Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More
Merck’s Keytruda Combo for Urothelial Carcinoma Gets EU Approval: The European Commission granted approval to Merck’s Keytruda in combination with Astellas/Pfizer’s antibody-drug conjugate ...